500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18+
SponsorNational Taiwan University Hospital

About this trial

This is a study to compare the treatment effect of different doses of ceftriaxone for gonorrhea.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years or older man, and

having oropharyngeal, anorectal or urogenital N. gonorrhoeae infection confirmed by culture or a positive NAAT

Disqualifiers

Suspicion of a complicated N. gonorrhoeae infection. Complicated N. gonorrhoeae infection is defined as the presence of epididymitis, arthritis, bacteremia, conjunctivitis, or disseminated gonococcal infection.

Use of systemic cephalosporins, doxycycline, or azithromycin at the screening visit or within 30 days prior to the enrollment visit is prohibited. Participants who require immediate antibiotic treatment at the screening visit, based on clinician judgment or shared decision-making with the participant, without awaiting PCR or culture confirmation, will be excluded from the study. Use of doxycycline for post-exposure prophylaxis (Doxy-PEP) is permitted.

A NAAT test positive for C. trachomatis or M. genitalium at the screening visit.

A history of allergy or intolerance to ceftriaxone, penicillins, or lidocaine, in alignment with the contraindications listed in the Sintrix (ceftriaxone) injection package insert. Allergy or intolerance is defined as the occurrence of adverse symptoms following antibiotic administration, including but not limited to skin rash, pruritus, dyspnea, angioedema, anaphylaxis, dizziness, nausea, vomiting, headache, or diarrhea. Laboratory abnormalities include cytopenias, eosinophilia, and elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or creatinine. Penicillins include natural penicillins (e.g., penicillin G), aminopenicillins (e.g., amoxicillin, ampicillin), penicillinase-resistant penicillins (e.g., oxacillin, dicloxacillin), extended-spectrum penicillins (e.g., piperacillin), and other agents classified within the penicillin class.

Trial design

Design model

Parallel

Treatments tested in this trial

  • ceftriaxone 500-mg

    Drug

    single-dose ceftriaxone 500-mg intramuscular injection, dissolved in 2 mL of 1% lidocaine hydrochloride solution

  • ceftriaxone 1000-mg

    Drug

    single-dose ceftriaxone 1000-mg intramuscular injection, dissolved in 3.5 mL of 1% lidocaine hydrochloride solution

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: 500-mg ceftriaxoneExperimental treatment 1 intervention
Group B: 1000-mg ceftriaxoneActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Treatment response of UGI

The proportion of participants with successful treatment of UGI, defined as a NAAT-negative and, if applicable, a culture-negative result of the primary anatomic sites of infection 7-14 days after treatment; a culture-negative result is required only if N. gonorrhoeae culture was positive at the screening visit.

Time frame
From enrollment to 14 days after treatment

Secondary outcomes

1

Symptom duration

Symptom duration, including dysuria, genital discharge, sore throat, anorectal pain, rectal bleeding, and rectal discharge, in the subgroup of patients who have baseline symptoms attributable to UGIs.

Time frame
From enrollment to 14 days after treatment
2

Treatment-related adverse events

Treatment-related adverse events until 14 days after treatment.

Time frame
From enrollment to 14 days after treatment
3

MIC of ceftriaxone of isolates

MIC of ceftriaxone of isolates at screening and test-of-cure (TOC) visits.

Time frame
From enrollment to 14 days after treatment
4

NG-MAST

NG-MAST at screening and TOC visits.

Time frame
From enrollment to 14 days after treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Taiwan University Hospital

Lead sponsor

National Taiwan University Hospital Hsin-Chu Branch

Collaborator

Far Eastern Memorial Hospital

Collaborator

National Taiwan University Hospital, Yun-Lin Branch

Collaborator